2022
Lung Cell Atlases in Health and Disease
Adams T, Marlier A, Kaminski N. Lung Cell Atlases in Health and Disease. Annual Review Of Physiology 2022, 85: 47-69. PMID: 36351366, DOI: 10.1146/annurev-physiol-032922-082826.Peer-Reviewed Original ResearchConceptsCell atlasesSingle-cell profiling technologiesLung biologyProfiling technologiesCell typesCellular morphologyProgressive lung diseaseCellular measurementsHuman lung biologyGas exchangeLung diseaseComplex branching structuresRecent advancesDiseaseIndividual markersBiologyBranching structureUnprecedented levelHealthStructural changesFrom COVID to fibrosis: lessons from single-cell analyses of the human lung
Justet A, Zhao AY, Kaminski N. From COVID to fibrosis: lessons from single-cell analyses of the human lung. Human Genomics 2022, 16: 20. PMID: 35698166, PMCID: PMC9189802, DOI: 10.1186/s40246-022-00393-0.Peer-Reviewed Original ResearchConceptsSingle-cell RNA-sequencing technologySingle-cell RNA sequencingRNA-sequencing technologyGene expression patternsMonocyte-derived macrophage populationSingle-cell analysisCell populationsLung diseaseCellular phenotypesRNA sequencingExpression patternsGene expressionAberrant repairMultiple tissuesPulmonary fibrosisMechanisms of diseaseFibrotic interstitial lung diseaseLife-threatening complicationsProgressive lung diseaseCOVID-19 pneumoniaInterstitial lung diseaseParenchymal lung diseaseAcute viral diseaseMacrophage populationsNovel cell
2020
CMH-Small Molecule Docks into SIRT1, Elicits Human IPF-Lung Fibroblast Cell Death, Inhibits Ku70-deacetylation, FLIP and Experimental Pulmonary Fibrosis
Konikov-Rozenman J, Breuer R, Kaminski N, Wallach-Dayan SB. CMH-Small Molecule Docks into SIRT1, Elicits Human IPF-Lung Fibroblast Cell Death, Inhibits Ku70-deacetylation, FLIP and Experimental Pulmonary Fibrosis. Biomolecules 2020, 10: 997. PMID: 32630842, PMCID: PMC7408087, DOI: 10.3390/biom10070997.Peer-Reviewed Original ResearchMeSH KeywordsAcetylationAnimalsBinding SitesCASP8 and FADD-Like Apoptosis Regulating ProteinCell LineCell SurvivalDisease Models, AnimalFibroblastsGene Expression RegulationHumansHydroxamic AcidsIdiopathic Pulmonary FibrosisKu AutoantigenLungMaleMiceMice, Inbred C57BLModels, MolecularMolecular Docking SimulationProtein ConformationProtein StabilitySirtuin 1ConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisFibrotic-lung myofibroblastsProgressive lung diseaseExperimental pulmonary fibrosisFibroblast cell deathLung diseaseLung fibrosisLung sectionsVital organsFlow cytometryFibrosisMyofibroblast resistanceRegenerative capacityFLIP levelsCell survivalCell deathImmunoblotCmHSIRT1Activity inhibitionUseful strategySmall moleculesBleomycinMyofibroblasts
2015
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Wilkes DS, Chew T, Flaherty KR, Frye S, Gibson KF, Kaminski N, Klemsz MJ, Lange W, Noth I, Rothhaar K. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. European Respiratory Journal 2015, 45: 1393-1402. PMID: 25614165, DOI: 10.1183/09031936.00105314.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisIPF patientsPulmonary fibrosisHigh-dose cohortLow-dose cohortSerious adverse eventsPhase 1 studyProgressive lung diseaseType V collagenPrecision medicine approachMatrix metalloproteinase-7Acute exacerbationIPF trialsOral immunotherapyAdverse eventsPlacebo armLung functionPoor prognosisVital capacityLung diseaseImmune responsePatientsMetalloproteinase-7Potential efficacyMedicine approach